Accessibility Menu
U.s. NeuroSurgical logo

U.s. NeuroSurgical(OTC) USNU

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)+1,340%
5 Year+221%
1 Year-36%
1 Month-11%
N/A
U.s. NeuroSurgical last closing stock price
MetricPriceDate
Last closeUSD 0.902026-08-06
U.s. NeuroSurgical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.902026-07-23
1 month-10.89%USD 1.012026-06-29
3 month-10%USD 1.002026-05-08
Year to date-28.57%USD 1.262025-12-26
1 year-35.71%USD 1.402025-08-06
3 year+800%USD 0.102023-08-04
5 year+221.43%USD 0.282021-08-06
Since inception+1,340%USD 0.061999-10-21

U.s. NeuroSurgical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.42M

Net Income (TTM)

-$8.67M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Mar 31, 2023

USNU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About U.s. NeuroSurgical

U.S. NeuroSurgical Holdings, Inc. operates specialized facilities for stereotactic radiosurgery, utilizing advanced gamma knife technology. This innovative approach effectively treats brain tumors and various cerebral malformations, positioning the company as a key player in the healthcare sector.

Products and Services
  • Specialized facilities for stereotactic radiosurgery
  • Gamma knife technology for non-invasive brain treatments
  • Comprehensive care for cerebral malformations
Growth Outlook
  • Recent quarterly revenue increased to $1,398,000, showing potential for growth
  • Strong cash position with $2,602,000 available as of March 31, 2026
  • Market demand for non-invasive surgical options continues to rise
Financial Highlights
  • Trailing twelve months revenue of $4,000,000, indicating steady performance
  • Operating loss reduced to $1,298,000 in Q1 2026 from $1,802,000 in Q4 2025
  • Current ratio of 2.40 suggests strong liquidity position
U.S. NeuroSurgical Holdings, Inc. has established itself in the healthcare industry by focusing on innovative treatment options for neurological conditions. The company's use of gamma knife technology allows for precise, non-invasive procedures, which are increasingly sought after in modern medicine. The growth outlook appears promising, with recent revenue trends indicating an upward trajectory. The company’s cash reserves provide a solid foundation for future investments and operational stability. Additionally, the healthcare sector's ongoing shift towards non-invasive treatments aligns well with the company's offerings, potentially driving further demand. Financially, the company has shown resilience, with a notable increase in quarterly revenue and a significant reduction in operating losses. The current ratio reflects a healthy liquidity position, which is crucial for navigating the challenges of the healthcare market. Overall, U.S. NeuroSurgical Holdings, Inc. presents an intriguing opportunity for investors interested in the evolving landscape of medical technology and treatment solutions.
AI Generated • Jul 23, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

87

CEO

Prasad A. Jeereddi, MD

Website

www.usneurosurgical.com

Headquarters

Ontario, MD 20850, US

USNU Financials

Key Financial Metrics (TTM)

Gross Margin

9.70%

Operating Margin

-194.47%

Net Income Margin

-358.13%

Return on Equity

-190.85%

Return on Capital

-71.74%

Return on Assets

-159.65%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$235.00K

Operating Income

-$4.71M

EBITDA

$470.00K

Operating Cash Flow

-$3.90M

Capital Expenditure

$0.00

Free Cash Flow

-$3.90M

Cash & ST Invst.

$2.60M

Total Debt

$29.00K

U.s. NeuroSurgical Performance Analysis

U.s. NeuroSurgical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 1,024,000N/A
U.s. NeuroSurgical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-3136.5%
U.s. NeuroSurgical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.1750.8%
20232023-12-31USD -0.09-48.4%
20242024-12-31USD -0.1352.0%
20252025-12-31USD -0.35158.3%
U.s. NeuroSurgical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.4%
Q32025-09-30-142.7%
Q42025-12-31-400.0%
Q12026-03-3180.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.40M

N/A

Gross Profit

$117.00K

+1400.0%

Gross Margin

8.37%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

3

N/A

Net Income

-$1.29M

-205.2%

EBITDA

$19.00K

+104.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.60M

-29.6%

Total Debt

$29.00K

-54.7%

Accounts Receivable

$245.00K

+24400.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$29.00K

-58.6%

Return on Assets

-1.60%

N/A

Return on Invested Capital

-1.16%

N/A

Free Cash Flow

-$1.26M

-52.6%

Operating Cash Flow

-$1.26M

-322.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCHMPharmChem, Inc.
$3.75+0.27%
HQDAHQDA Elderly Life Network Corp.
$0.13+2.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
SPCXSpace Exploration Technologies
$114.92+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%

Questions About USNU

What is the current price of U.s. NeuroSurgical?

U.s. NeuroSurgical is trading at N/A per share.

What is the 52-week range for U.s. NeuroSurgical?

Over the past 52 weeks, U.s. NeuroSurgical has traded between N/A and N/A.

How much debt does U.s. NeuroSurgical have?

As of the most recent reporting period, U.s. NeuroSurgical reported total debt of $29.00K.

How much cash does U.s. NeuroSurgical have on hand?

U.s. NeuroSurgical reported $2.60M in cash and cash equivalents in its most recent financial results.

What is U.s. NeuroSurgical’s dividend yield?

U.s. NeuroSurgical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services